+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
T

Actively Recruiting

This research aims to evaluate treatment options for adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have experienced disease progression after first-line treatment with pembrolizumab, with or without chemotherapy. The study focuses on patients who need a second line of treatment and investigates the objective response rate to a combination therapy called PCC Paclitaxel, Carboplatin, and Cetuximab. It also monitors disease progression, treatment tolerance, and quality of life over 12 months. Participants receive the PCC protocol, which involves intravenous injections of paclitaxel, carboplatin, and cetuximab administered in cycles lasting one week each for 16 cycles. The carboplatin and paclitaxel are given three weeks out of four, alongside weekly cetuximab. After these cycles, maintenance treatment with cetuximab is given every 14 days until unacceptable side effects, disease progression, or death occurs. During the study, patients will undergo evaluations every 90 days for up to 12 months to measure tumor response and progression. Researchers will assess survival outcomes, treatment safety, and quality of life. Follow-ups may continue according to local practice for up to five years, including monitoring progression-free survival and overall survival. The total participation duration is 12 months, with ongoing safety and quality of life assessments.

Age: 18Years +All GendersPhase 2
5 locations
R

Actively Recruiting

Researchers are evaluating the new 2024 McDonald criteria for diagnosing multiple sclerosis MS compared to the previous 2017 version. These updated criteria introduce new diagnostic elements such as additional imaging techniques, ophthalmological data, and the kappa index test in cerebrospinal fluid. The study aims to see if the 2024 criteria improve early diagnosis rates and to determine the best threshold for the kappa index test. The study involves applying both the 2017 and 2024 McDonald diagnostic criteria to patients consulting neurology departments for suspected MS between September 2025 and December 2026. Patients undergo routine diagnostic tests including brain MRIs, optic nerve imaging, ophthalmological exams, and cerebrospinal fluid analysis. The kappa index test is performed for patients seen at Nancy University Hospital, with no additional procedures beyond standard care. Follow-up assessments continue over two years to compare diagnosis rates using both criteria. Participants will be followed through their usual clinical visits and standard care procedures, with data collected from imaging reports, neurological assessments, and laboratory tests. Researchers will measure the percentage of patients diagnosed with MS at initial assessment and at intervals over two years. They will also evaluate the diagnostic value of each test and identify optimal thresholds for the kappa index. The study will help clarify which tests are most useful for timely MS diagnosis and may guide future updates to diagnostic guidelines.

All AgesAll Genders
2 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Researchers are studying the effects of early treatment with Empagliflozin in patients experiencing cardiogenic shock, a serious heart condition where the heart suddenly cant pump enough blood. This trial aims to see if adding Empagliflozin to standard care can reduce death, the need for heart transplantation or mechanical assistance, and rehospitalization, while improving heart function over 12 weeks. The study is a randomized, open-label Phase 3 trial sponsored by Central Hospital, Nancy, France. Participants are randomly assigned to receive either Empagliflozin 10 mg daily, taken by mouth or through a tube if intubated, alongside standard management, or standard management alone. The treatment lasts for 12 weeks. After hospitalization, patients in the standard group may receive SGLT2 inhibitors according to routine care guidelines. The trial focuses on the early use of Empagliflozin right after cardiogenic shock. During the study, patients will have heart function monitored by ultrasound to measure left ventricular ejection fraction and other heart performance indicators. Researchers will track outcomes including time to death, heart transplantation, mechanical assistance, and rehospitalization for heart failure within 12 weeks. Kidney function and various blood tests will also be assessed. The total study participation lasts at least 12 weeks after randomization, during which safety and effectiveness measures are closely observed.

Age: 18Years +All GendersPhase 3
8 locations
E

Actively Recruiting

Researchers are evaluating the early use of levosimendan compared to a placebo added to standard inotropic treatment in adults with cardiogenic shock, a condition with a high mortality rate of about 40%. The study aims to determine whether levosimendan can improve heart function and speed recovery by allowing earlier discontinuation of dobutamine, which is commonly used but lacks strong evidence for its effectiveness in this setting. This is a phase 3 randomized clinical trial with triple masking to ensure unbiased results. Participants are randomly assigned to one of two groups an experimental group receiving levosimendan infusion and a control group receiving a placebo infusion, both alongside conventional inotropic therapy. The infusion is administered continuously over 24 hours, starting at 0.1 mcgkgmin and potentially increased to 0.2 mcgkgmin after 2 to 4 hours if needed. The study evaluates the combination of levosimendan or placebo with current standard care, following strict dosing protocols. During the study, participants will be closely monitored for mortality, use of life support devices, dialysis, and other cardiovascular events at multiple time points up to one year. Researchers will measure outcomes including death rates, need for extracorporeal life support, dialysis, heart transplant, and hospital stay duration. Safety will be assessed alongside heart function indicators and biomarkers. The total follow-up extends to 12 months after randomization to capture both short- and long-term effects.

Age: 18Years +All GendersPhase 3
28 locations
N

Actively Recruiting

Researchers are studying type I interferonopathies, which are rare genetic autoinflammatory disorders mainly affecting children but sometimes adults. These conditions often involve the central nervous system, joints, and occasionally blood abnormalities or immune deficiencies. They are caused by over-activation of the type I interferon pathway and tend to resist standard immunosuppressive treatments. The goal is to better understand the natural course of these diseases and their diverse clinical features. This observational study follows patients with genetically confirmed type I interferonopathies over a long period. It aims to characterize disease progression, identify immune factors linked to specific genotypes, find biomarkers for diagnosis and monitoring, and observe treatment responses based on patient phenotypes and genotypes. The study does not involve experimental treatments but collects data to improve future therapies. Participants will be monitored from 2025 through 2045. Data collection includes tracking disease evolution, immunological profiles, and treatment effectiveness. Researchers aim to clarify pathophysiological mechanisms and patient subgroups to guide personalized treatment options. Participation involves regular evaluations without experimental interventions, contributing to knowledge that supports better clinical trial design and patient care.

All AgesAll Genders
32 locations
E

Actively Recruiting

Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.

Age: 18Years +All GendersPhase Not Applicable
150 locations